Machina Capital S.A.S. Buys 13,282 Shares of The Cooper Companies, Inc. (NASDAQ:COO)

Machina Capital S.A.S. lifted its stake in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 363.5% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 16,936 shares of the medical device company’s stock after buying an additional 13,282 shares during the quarter. Machina Capital S.A.S.’s holdings in Cooper Companies were worth $1,557,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. Ashton Thomas Securities LLC acquired a new stake in shares of Cooper Companies during the 3rd quarter worth approximately $25,000. Covestor Ltd grew its position in shares of Cooper Companies by 144.9% during the 3rd quarter. Covestor Ltd now owns 338 shares of the medical device company’s stock worth $37,000 after buying an additional 200 shares during the period. Byrne Asset Management LLC acquired a new stake in shares of Cooper Companies during the 4th quarter worth approximately $33,000. Brown Brothers Harriman & Co. grew its position in Cooper Companies by 191.0% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 419 shares of the medical device company’s stock valued at $46,000 after purchasing an additional 275 shares during the period. Finally, West Financial Advisors LLC acquired a new stake in Cooper Companies in the 4th quarter valued at $49,000. Institutional investors and hedge funds own 24.39% of the company’s stock.

Analyst Upgrades and Downgrades

COO has been the subject of several research reports. StockNews.com downgraded shares of Cooper Companies from a “buy” rating to a “hold” rating in a research report on Wednesday, December 11th. Stifel Nicolaus reduced their price target on shares of Cooper Companies from $115.00 to $105.00 and set a “buy” rating for the company in a research report on Friday. JPMorgan Chase & Co. reduced their price target on shares of Cooper Companies from $120.00 to $110.00 and set an “overweight” rating for the company in a research report on Friday. Needham & Company LLC reissued a “hold” rating on shares of Cooper Companies in a research report on Friday. Finally, Citigroup reduced their price target on shares of Cooper Companies from $115.00 to $110.00 and set a “buy” rating for the company in a research report on Friday. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $111.89.

Cooper Companies Price Performance

Shares of NASDAQ:COO opened at $85.00 on Friday. The company has a current ratio of 1.91, a quick ratio of 1.12 and a debt-to-equity ratio of 0.32. The stock’s fifty day simple moving average is $92.52 and its two-hundred day simple moving average is $99.45. The Cooper Companies, Inc. has a 1-year low of $82.61 and a 1-year high of $112.38. The stock has a market cap of $16.96 billion, a PE ratio of 43.59, a price-to-earnings-growth ratio of 2.25 and a beta of 1.02.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings data on Thursday, March 6th. The medical device company reported $0.92 earnings per share for the quarter, meeting the consensus estimate of $0.92. The business had revenue of $964.70 million for the quarter, compared to analysts’ expectations of $981.25 million. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. As a group, analysts forecast that The Cooper Companies, Inc. will post 3.98 EPS for the current fiscal year.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.